Hualan Vac(SZ:301207) Xin Lang Cai Jing·2025-11-04 05:55Core Viewpoint - Hualan Biological Engineering Inc. experienced a stock price increase of 6.54%, reaching 22.48 CNY per share, with a trading volume of 299 million CNY and a turnover rate of 2.35%, resulting in a total market capitalization of 13.511 billion CNY [1] Company Overview - Hualan Biological Engineering Inc. is located at No. 1 Jia, Hualan Avenue, Xinxiang City, Henan Province, and was established on November 9, 2005. The company went public on February 18, 2022. Its main business involves the research, production, and sales of human vaccines [1] - The revenue composition of the company is primarily from vaccine products, accounting for 98.11%, while other sources contribute 1.89% [1] Shareholder Information - Among the top ten circulating shareholders of Hualan Vaccine, a fund under Southern Fund ranks first. The Southern CSI 1000 ETF (512100) reduced its holdings by 8,700 shares in the third quarter, now holding 1.6522 million shares, which represents 0.28% of the circulating shares. The estimated floating profit today is approximately 2.28 million CNY [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a current scale of 76.63 billion CNY. Year-to-date returns are 28.02%, ranking 2029 out of 4216 in its category; over the past year, returns are 28.69%, ranking 1809 out of 3896; and since inception, returns are 13.29% [2] - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 6 years and 364 days. The total asset scale under management is 122.76 billion CNY, with the best fund return during the tenure being 179.04% and the worst being -15.93% [2]